FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Cipla India Plant Receives FDA-483

[ Price : $8.95]

FDA sends India-based Cipla Ltd. a two-item Form FDA-483 after a recent inspection at its Madhya Pradesh, India manufacturing plan...

Pfizer Required to Conduct Paxlovid Covid Rebound Trial

[ Price : $8.95]

FDA revises a Pfizers emergency use authorization for Paxlovid (nirmatrelvir co-packaged with ritonavir) for treating mild-to-mode...

Visibly At-Home Vision Test Cleared

[ Price : $8.95]

FDA clears a Visibly 510(k) for its Visibly Digital Acuity Product (VDAP), an at-home digital vision testing platform for determin...

Info Collection on CDRH Appeals Processes

[ Price : $8.95]

Federal Register notice: FDA sends to OMB an information collection extension entitled Center for Devices and Radiological Health ...

False Claims Act Used in Off-Label Cases: Attorney

[ Price : $8.95]

Attorney Keeley McCarty warns medical device manufacturers that the government is pursuing False Claims Act cases against companie...

CDER Working on Pediatric Extrapolation Framework

[ Price : $8.95]

CDER researchers say they are developing a non-inferiority paradigm to assess exposure-response similarity between pediatric and a...

Medical Device Recalls Up in 2nd Quarter: Sedgwick

[ Price : $8.95]

The Sedgwick Recall Index says medical device recalls soared in the second quarter of 2022, while drug recalls remained level with...

Draft Guide on Contact Lens Care Labeling

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Hydrogen Peroxide- Based Contact Lens Care Products: Consum...

FDA Lifts 1 Emavusertib Clinical Hold

[ Price : $8.95]

FDA lifts a partial clinical hold on the Curis TakeAim Lymphoma study of emavusertib.

Final Guide on Replacement Reagent for IVDs

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Replacement Reagent and Instrument Family Policy for In Vit...